FEATURES of the COURSE of COVID-19 in ELDERLY PATIENTS with IMMUNO-INFLAMMATORY RHEUMATIC DISEASES (PRELIMINARY DATA)
Annals of the Rheumatic Diseases
; 81:1683, 2022.
Article
in English
| EMBASE | ID: covidwho-2009025
ABSTRACT
Background:
It is assumed that patients with immuno-infammatory rheumatic diseases (IIRDs) in old age are susceptible to a more severe course of COVID-19 both due immunological disorders (autoimmune disease and its activity, immuno-suppressive therapy, immunosenescence leading to systemic subclinical chronic infammation with increased secretion of IL-6, IL-1, IL-18, TNF-α) and due to the presence of comorbid pathology. There are no Russian data on the course of COVID-19 in elderly patients with IIRDs.Objectives:
To study the features of the course of COVID-19 in elderly patients with IIRDs.Methods:
The study included 93 patients with IIRDs 72 women, 21 men, average age 67.5±6.1 years. Of them, 62 patients suffered from rheumatoid arthritis, 9-systemic sclerosis, 5-ankylosing spondylitis, 4-Sjogren's disease, 4-systemic vasculitis, 3-psoriatic arthritis, 2-osteoarthritis, 1 systemic lupus erythematosus, 1-polymyositis, 1-rheumatic polymyal-gia, 1-gout. At the moment of COVID-19, 10 patients had high activity of IIRDs, 26-moderate, 40-low, 17-remission. 69 patients were treated with disease-modifying antirheumatic drugs-DMARDs (40-methotrexate, 12-lefunomide, 8-sulfasalazine, 7-hydroxychloroquine), 45-glucocorticoids (34-low doses, 11-medium or high doses). 36 patients received biologic or target DMARDs 24-rituximab (the interval from the last administration to the development of COVID-19 symptoms averaged 7 months), 4-TNF-α inhibitors, 3-abatacept, 2-secukinumab, 1-tofacitinib, 1-baricitinib, 1 ustekinumab. Comorbidities included hypertension (n=74), coronary artery disease (n=27), obesity (n=17), diabetes mellitus (n=8), bronchial asthma (n=5), chronic obstructive pulmonary disease (n=4), chronic kidney disease (n=3). The patients were interviewed by a research doctor, additional information was obtained from medical documentation.Results:
The most common symptoms of COVID-19 were fever-67.7%, weakness/drowsiness-53.7%, cough-48.4%, as well as anosmia and dyspnea-35.5% each, headache-20.4%, body aches-16.1%, congestion nose-8.6%, chest pain-7.5%, dysgeusia-5.4%, diarrhea/vomiting-3.2%. According to CT chest scan, 8 patients had 0% of lung damage, 31-25%, 32-50%, 12-75%, in other cases the study was not carried out (n=9) or data are not available (n=1). In 2 patients the course of COVID-19 was complicated by bacterial pneumonia, in 1-bacterial-fungal. An asymptomatic course was noted only in 2 patients (PCR+/IgM +, CT 0, close contact with a confrmed case of COVID-19). Recovery was noted in 90 patients, fatal outcome-in 3. Exacerbation of IIRDs after COVID-19 was noted in 48.4% of patients, which required intensifying antirheu-matic therapy.Conclusion:
Preliminary data indicate that COVID-19 is characterized by moderate and severe course in elderly patients with IIRDs. Further studies are required to identify risk factors for severe course and complications in order to provide timely qualifed care.
abatacept; baricitinib; disease modifying antirheumatic drug; endogenous compound; glucocorticoid; hydroxychloroquine; immunoglobulin M; methotrexate; rituximab; salazosulfapyridine; secukinumab; tofacitinib; tumor necrosis factor inhibitor; ustekinumab; aged; ankylosing spondylitis; anosmia; asthma; bacterial pneumonia; chronic kidney failure; chronic obstructive lung disease; comorbidity; complication; conference abstract; coronary artery disease; coronavirus disease 2019; coughing; diabetes mellitus; diarrhea; disease exacerbation; drowsiness; drug megadose; drug therapy; dysgeusia; dyspnea; fatality; female; fever; gout; headache; human; hypertension; low drug dose; lung injury; major clinical study; male; medical documentation; nose; obesity; outcome assessment; polymyositis; preliminary data; psoriatic arthritis; remission; rheumatic disease; rheumatoid arthritis; risk factor; Sjoegren syndrome; systemic lupus erythematosus; systemic sclerosis; systemic vasculitis; thorax pain; vomiting; weakness
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS